Meredith RF - Search Results

1

Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.

Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R. Meredith RF, et al. Cancer Biother Radiopharm. 2014 Feb;29(1):12-7. doi: 10.1089/cbr.2013.1531. Epub 2013 Nov 14. Cancer Biother Radiopharm. 2014. PMID: 24229395 Free PMC article. Clinical Trial.

2

Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.

Meredith R, You Z, Alvarez R, Partridge E, Grizzle W, LoBuglio A. Meredith R, et al. Cancer Biother Radiopharm. 2012 Feb;27(1):36-40. doi: 10.1089/cbr.2011.1111. Epub 2012 Jan 12. Cancer Biother Radiopharm. 2012. PMID: 22239432 Free PMC article.

3

Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.

Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P, Morgan D, Fan J, Straughn JM Jr. Meredith R, et al. J Nucl Med. 2014 Oct;55(10):1636-42. doi: 10.2967/jnumed.114.143842. Epub 2014 Aug 25. J Nucl Med. 2014. PMID: 25157044 Free PMC article. Clinical Trial.

4

Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.

Shen S, Forero A, Meredith RF, LoBuglio AF. Shen S, et al. Among authors: meredith rf. Cancer Biother Radiopharm. 2011 Feb;26(1):127-33. doi: 10.1089/cbr.2010.0864. Cancer Biother Radiopharm. 2011. PMID: 21355784

5

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM. Meredith RF, et al. Am J Clin Oncol. 2018 Jul;41(7):716-721. doi: 10.1097/COC.0000000000000353. Am J Clin Oncol. 2018. PMID: 27906723 Free PMC article.

6

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.

Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM Jr, Kilgore LC, Grizzle WE, Schlom J, LoBuglio AF. Meredith RF, et al. Cancer Biother Radiopharm. 2001 Aug;16(4):305-15. doi: 10.1089/108497801753131381. Cancer Biother Radiopharm. 2001. PMID: 11603001 Clinical Trial.

7

Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.

Meredith R, Shen S, Macey D, Khazaeli MB, Carey D, Robert F, LoBuglio A. Meredith R, et al. Cancer Biother Radiopharm. 2003 Jun;18(3):393-404. doi: 10.1089/108497803322285134. Cancer Biother Radiopharm. 2003. PMID: 12954125

8

Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.

Shen S, Meredith R, Duan J, Forero A, Breitz H, Khazaeli MB, Brezovich I, LoBuglio A. Shen S, et al. Cancer Biother Radiopharm. 2005 Feb;20(1):110-8. doi: 10.1089/cbr.2005.20.110. Cancer Biother Radiopharm. 2005. PMID: 15778590

9

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF. Alvarez RD, et al. Among authors: meredith rf. Clin Cancer Res. 2002 Sep;8(9):2806-11. Clin Cancer Res. 2002. PMID: 12231520 Clinical Trial.

10

Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.

Shen S, Meredith RF, Duan J, Brezovich I, Khazaeli MB, LoBuglio AF. Shen S, et al. Among authors: meredith rf. Cancer Biother Radiopharm. 2003 Apr;18(2):209-15. doi: 10.1089/108497803765036373. Cancer Biother Radiopharm. 2003. PMID: 12804046 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters